The DeSci Podcast

Welcome to this episode of the DeSci Podcast, where we dive deep into the technology behind IP-NFTs and explore the possibilities of decentralized data storage.

In this episode, Stefan Adolf, a senior web3 engineer at Molecule, and Benji Leibowitz, a former biotech venture capitalist and now a product manager at Molecule, discuss the modularity of IP-NFTs, the advantages of ERC721, 1155, and 3525 token standards.

We also discuss the benefits of Arweave and IPFS for metadata and storage, Lit Protocol and unlocking data, custodial wallets and MPC providers, the SDK for developers, and the possibilities of permissionless minting and open source strategies with v2 and v3 of the IP-NFT.

We hope you can learn a lot about the amazing possibilities of the decentralized tech stack and how you can build with IP-NFTs with this episode and feel free to use the timestamps below to navigate through the episode.

Navigate through the topics discussed in this podcast using the timestamps below.

____

Timestamps:

00:00 - 01:42 Intro
01:42 - 04:30 What is the IP-NFT and who should use it?
04:30 - 08:40 Token Advantages (ERC721, 1155, and 3525)
08:40 - 11:18 IP-NFT V2 (Mint-passes and Reservations)
11:18 - 12:40 Who is the ideal user for a min-pass?
12:40 - 17:24 Where is the metadata of an IP-NFT stored, and how is it structured?
17:24 - 25:19 Difference between web3 and web2 storage
25:19 - 29:21 Content gating with DAO tools
29:21 - 34:56 The role of Lit-Protocol within the IP-NFT
34:56 - 49:00 Frontend of the IP-NFTs and on web3 wallets
49:00 - 51:59 When can people start building on this technology (wen SDK?)
51:59 Outro

____

If you want to watch the Podcast on YouTube, you can find all the important links below. And if you want to join us on the show as a speaker or have guest ideas; please mail us at [email protected]
linktr.ee/thedescipodcast

Special thanks to:

Heinrich Tessendorf (Host): https://twitter.com/Heintess_GM
Stefan Adolf: https://twitter.com/stadolf
Benji Leibowitz: https://twitter.com/benjileibo

____

Let's connect:
Website: https://molecule.to/
Twitter: https://twitter.com/Molecule_dao
Discord: https://discord.com/invite/moleculedao

Welcome to another episode of the DeSci Podcast. In this episode, Stanley Bishop, AKA Science Stanley, data scientist and head of data science at LabDAO talks about AI, what it means to be a data scientist and how it intersects with decentralized approaches. We also talk about how this can be applied across individual health, collective health, the planets, genome sequencing and language models and what this could mean for the future of the organization and the future of work.

Stanley Bishop also talks about LabDAO’s collaboration with "Research to the People" in order to build an integrated and traditional data marketplace where treatments can be shared between physicians so they can compare notes and figure out the best clinical path for their patients which can be impactful for patients that might have rare or complex conditions, New Atlantis DAO and its mission to provide a solution for climate change and many more.

Navigate through the topics discussed in this podcast using the timestamps below.

____

Timestamps:

0:00 Intro
1:38 What is a data scientist?
3:09 How has that led you to Lab DAO?
04:51 What does being a data scientist within a DeSci organization look like?
06:15 What projects are LabDAO working on right now?
09:18 LabDAO overall structure.
11:56 LabDAO's partnership with Research to the people.
16:17 The future of translational research.
18:36 What else is possible with DeSci?
23:42 New Atlantis DAO.
31:07 Recommendations for scientists transitioning into Web 3.
34:09 Collaboration with TalentDAO.
42:13 Other use cases of TalentDAO.
46:16 What AI trend do you expect to gain traction in the future?
50:39 Remunerating contributors.

____

If you want to join us on the show as a speaker or have guest ideas, please shoot us a mail at [email protected]

Special thanks to:

Erin Magennis (Host): https://twitter.com/erinmagennis
Stanley:https://twitter.com/ScienceStanley

____

Let's connect:

Website: https://bit.ly/3d6nh2C
Twitter: https://twitter.com/Molecule_dao
Discord: https://discord.com/invite/moleculedao

Welcome to Episode Nr. 2 of the DeSci Podcast - Today we're exploring the decentralized science reformation together with no other than Balaji Srinivasan! We're incredibly proud to be joined by such a smart and well-known mind as a second guest on "The DeSci Podcast" show!

Topics of this episode:
→ Key factors holding back scientific progress and how to change it (also via DeSci). 🧪
→ What role does AI play here?
→ The future of human optimalism.
→ How to make predictions in technology?
(+ many more & some great advice for DeSci builders at the end from Balaji)

Due to his nature, we're slipping in many other interesting topics while tackling those above! 💙
A huge thanks again to Balaji for taking the time and for the valuable input - We hope you all can take something away from this episode on your DeSci journey.

Feel free to skip around the timestamps to find your favorite topics and thanks again for tuning in! Also, if you prefer listening to podcasts on audio apps, feel free to search for "How To DeSci" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps and the show-notes below.

If you want to join us on the show as a speaker or have guest ideas, please shoot us a mail at [email protected]
You'll also find all links to Spotify, Discord, Twitter and our website via the link below - https://linktr.ee/thedescipodcast
_____

Special thanks to:
Alex LaBossiere (Host): https://twitter.com/adlabossiere
Vincent Weisser (Chief Ecosystem Development Officer of Molecule): https://twitter.com/vincentweisser
Balaji Srinivasan: https://twitter.com/balajis
https://balajis.com/
https://balajis.com/the-purpose-of-technology/
https://thenetworkstate.com/

______

Timestamps:
00:00 - Intro
01:30 - Introduction of Balaji & The Network State
06:45 - Key factors holding back scientific progress
14:17 - How to change the research & funding structure
21:00 - Commonalities between New York Times and the nature of the Scientific Journals
38:00 - How does scientific progress unfold?
44:50 - Can AI be a dominant driver here?
49:10 - How to make predictions in technology
54:40 - The cyclical approach of history
01:02:48 - Advice for builders in the DeSci space
01:04:29 - Last words, book advice & outro

______

Show-notes of the episode:
https://twitter.com/balajis https://balajis.com/
https://balajis.com/the-purpose-of-technology/ https://thenetworkstate.com/
https://nexus.od.nih.gov/all/2021/11/18/long-term-trends-in-the-age-of-principal-investigators-supported-for-the-first-time-on-nih-r01-awards/ https://newscience.org/nih/
https://twitter.com/patrickc/status/1544067890403389441
https://project-evidence.github.io/ https://www.quantamagazine.org/in-new-math-proofs-artificial-intelligence-plays-to-win-20220307/ https://github.com/camoverride/lit/blob/master/The-Princeton-Companion-to-Mathematics.pdf

______

Let's connect:
Website: https://bit.ly/3BXtFUn
Twitter: https://twitter.com/Molecule_dao
Discord: https://discord.com/invite/moleculedao
Molecule - The future of medicine belongs to everyone

Welcome to Episode Nr. 3 of the DeSci Podcast - Today we're exploring the decentralized science space together with our CEO of Molecule and Vincent Weisser, our Chief Ecosystem Officer!

We're incredibly proud to finally speak in depth about our new project bio.xyz - Next to that, we are also digging into a lot of other interesting decentralized science topics. You can find all of them below, so you can skip around to find your favorite ones!

Topics & Timestamps:

00:00 - Intro
01:31 - Background Story of Paul
09:27 - Background Story of Vincent
13:43 - Why DeSci makes sense? (Valley of Death)
18:09 - How can BioDAOs solve current bottlenecks in science?
21:29 - How does a BioDAO work internally and what part plays Molecule here?
31:41 - What is bio.xyz and how does it relate to Molecule?
35:10 - bio.xyz cohort; PsyDAO
39:48 - bio.xyz cohort; AthenaDAO
42:30 - bio.xyz cohort; ValleyDAO
46:05 - bio.xyz cohort; HairDAO
50:00 - Structure of bio.xyz
51:13 - How can one apply for bio.xyz and advice for people who are interested to join
54:52 - How does the future of BiotechDAOs look like? (Vincent)
57:50 - How does the future of BiotechDAOs look like? (Paul)
01:02:52 - Ending & Outro

____

A huge thanks again to Vincent & Paul for taking the time and for the valuable input - We hope you all can take something away from this episode on your DeSci journey. Feel free to skip around the timestamps to find your favorite topics and thanks again for tuning in!
If you want to join us on the show as a speaker or have guest ideas, please shoot us a mail at [email protected]

You'll also find all links to YouTube, Discord, Twitter and our website on linktree here - https://linktr.ee/thedescipodcast

_____

Special thanks to:

Alex LaBossiere (Host): https://twitter.com/adlabossiere
(Check Alex his own podcast here: https://open.spotify.com/show/7lf0G6SBTArFlJYuHlPPoy?si=adcfa5f7a82d4708)
Vincent Weisser (Chief Ecosystem Development Officer of Molecule): https://twitter.com/vincentweisser
Paul Kohlhaas (CEO Molecule): https://twitter.com/paulkhls

Find out more about bio.xyz here:

Website: https://www.bio.xyz/
Twitter: https://twitter.com/bio_xyz
Discord: https://discord.gg/6ZeDSjhM2g

______

Let's connect:
Website: https://bit.ly/3d6nh2C
Twitter: https://twitter.com/Molecule_dao
Discord: https://discord.com/invite/moleculedao

Molecule - The future of medicine belongs to everyone

Welcome to Episode Nr. 4 of the DeSci Podcast - Today we're exploring the decentralized science space together with Jack Scannell! Jack coined the term Eroom's Law, which notes that the cost of new drug approvals is rising exponentially, in contrast to Moore's law, which notes that the number of transistors on a microchip doubles about every two years, though the cost of computers is halved.

In this podcast, Jack talks about how we can do better drug discovery, specifically, the tools and frameworks we can use to choose the right drug discovery model and feed that into investment decisions. His new paper in Nature Reviews Drug Discovery addresses exactly that: https://rdcu.be/cWTtO

In this podcast, Jack argues that quality beats quantity when it comes to assays, but actually the best thing is quality AND quantity. So it's better to test a small number of therapeutic candidates in a really good model than it is to test a very large number of computer candidates selected from the same universe in a model of low validity - the best example of this is in antimicrobials discovered around 1930 by Gerhard Domagk. Jacks says that the model validity used in Germany in the 1930's is better than the model validity used in the early 90's.

The technological barrier in drug R&D has shifted from chemistry to effectively the tools that tell you whether or not that chemistry is useful. It's not that we can't make compounds, we probably can in many cases make those compounds but what we can't do is we can't distinguish the ones that do something useful from the ones that don't. It's not that we can't identify targets, we can, but we can't tell the good ones from the bad ones - so the critical resource in drug R&D is probably the models, which Jack's paper calls "decision tools" that let you sift the good stuff from the bad stuff.

Jack on what interested him about VitaDAO and Molecule: You create value not by making current markets a little bit more efficient, you create value by making markets exist where none existed before. Outside of a few well-ventured universities, universities are terribly under-ventured and also the people at those universities don't have the right tools to present their material in such a way that it could be ventured so it struck him that providing a low transaction cost, standardized platform to make an eBay for IP might be an extremely valuable thing to do because you could create markets where none existed before.

Important links mentioned in the episode:
The new Nature Reviews Drug Discovery paper.
“Predictive validity in drug discovery: what it is, why it matters, and how to improve it”: https://rdcu.be/cWTtOThe
Emulate (organ chip) pre-print: “Qualifying a human Liver-Chip for predictive toxicology”: https://www.biorxiv.org/content/10.1101/2021.12.14.472674v4

____

A huge thanks again to Sebastian and Jack for taking the time and for the valuable input - We hope you all can take something away from this episode on your DeSci journey. If you want to join us on the show as a speaker or have guest ideas, please shoot us a mail at [email protected]

You'll also find all links to YouTube, Discord, Twitter and our website via the following link - https://linktr.ee/thedescipodcast

_____

Special thanks to:
Sebastian Brunemeier (Host): https://twitter.com/sebastian_gero
Jack Scannell: https://twitter.com/JackScannell13

______

Let's connect:
Website: https://bit.ly/3d6nh2C
Twitter: https://twitter.com/Molecule_dao
Discord: https://discord.com/invite/moleculedao

Molecule - The future of medicine belongs to everyone